3 stocks that soared stupendously this week 6-6-14


Published on

3 of this week's biggest healthcare stocks

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849
  • 3 stocks that soared stupendously this week 6-6-14

    1. 1. 3 Stocks That Soared Stupendously This Week
    2. 2. The overall market enjoyed a strong opening in June. Few stocks were as hot as those of these three health-care companies.
    3. 3. Shares of the biotech jumped 33% higher for the week. Vanda Pharmaceuticals (Nasdaq:VNDA) Source: Yahoo! Finance
    4. 4. • Vanda announced on Tuesday that the European Medicines Agency accepted its Marketing Authorization Application for Hetlioz • Hetlioz is an oral capsule used to treat Non- 24-Hour Sleep-Wake Disorder (Non-24), a disorder that disrupts the sleep-wake cycle for many blind individuals • Vanda gained approval for sale of Hetlioz in the U.S. in January • Around 130,000 people in Europe suffer from Non-24, making this week’s news a potentially big deal for Vanda Why Vanda shares vaulted
    5. 5. Shares of the biopharmaceutical firm specializing in cellular metabolism research surged 22% this week. Agios Pharmaceuticals (Nasdaq:AGIO) Source: Yahoo! Finance
    6. 6. • The operative word for Agios appears to be “anticipation” • Investors eagerly await phase 1 data for cancer drug AG-221 to be shared on June 14 at the European Hematology Association conference • Good news for AG-221 will also be positive for Celgene (Nasdaq:CELG), which claims primary commercial rights to the drug • Agios and Celgene are also collaborating on another phase 1 drug focusing on inhibiting the IDH protein Why Agios shares advanced
    7. 7. Shares of the biotech moved nearly 16% higher this week. MannKind Corporation (Nasdaq:MannKind) Source: Yahoo! Finance
    8. 8. • Anticipation also reigned for MannKind as investors wait on an FDA decision for the company’s inhaled insulin drug, Afrezza, scheduled for July 15 • No word has been announced yet on the big question mark for MannKind – whether or not the company has lined up a partner for commercialization of Afrezza • Expect intense investor interest over the company’s upcoming presentations at the Goldman Sachs and Wells Fargo health- care conferences Why MannKind leaped
    9. 9. • Vanda appears to be in good shape to win European approval for Hetlioz, which could propel shares even higher • FDA approval for Afrezza combined with landing a commercialization partner should keep MannKind shareholders jumping with joy • My nod for most likely to sustain its winning ways, though, goes to Agios • Assuming Agios reports positive results next week, the stock should keep the momentum going • It also wouldn’t be a surprise to see Agios eventually scooped up by its big partner, Celgene – which is sitting on a cash stockpile topping $5 billion Best pick to keep soaring?
    10. 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!